The record
| Class | nootropic |
|---|---|
| Also known as | PNB-0408, N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide |
| Chain length | - |
| Molecular weight | 504.6 Da |
| Half-life | ~2 hours |
| Route | Oral or SC |
| Studied for | - |
| Research use | Alzheimer's disease models; Cognitive enhancement research; Neuroprotection studies |
| What has been shown | Cognitive improvement in AD models; Increased dendritic spine density; Enhanced synaptic connectivity; Neuroprotection |
| How it works | Small molecule peptidomimetic derived from angiotensin IV. Binds hepatocyte growth factor (HGF) and its receptor c-Met with high affinity. Promotes: (1) HGF/c-Met dimerization, (2) Neurite outgrowth, (3) Synaptogenesis, (4) Dendritic spine formation, (5) BDNF expression. Crosses BBB readily. 7 million-fold more potent than BDNF for neurotrophic activity. |
| Patent status | Washington State University |
| Regulatory status | Research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 65%)
- Cognitive Enhancement / Focus (affection, 66%)
- Neuroprotection Signaling (affection, 51%)
- ADHD (illness, 60%)
- Alzheimer's disease (illness, 45%)
- Chronic inflammatory conditions (illness, 30%)
- Cognitive enhancement (illness, 33%)
- Diabetic neuropathy (illness, 30%)
- Neuropathic pain (illness, 30%)
- Sarcoidosis-associated small fiber neuropathy (illness, 30%)
- Stroke recovery (illness, 52%)
- Traumatic brain injury (illness, 52%)
- Vascular dementia (illness, 45%)
- Low mood (symptom, 67%)
- Brain fog or poor focus (symptom, 50%)
- Memory lapses (symptom, 75%)